Zhang Y, Singh V K, Yang V C
College of Pharmacy, University of Michigan, Ann Arbor 48109-1065, USA.
ASAIO J. 1998 Sep-Oct;44(5):M368-73. doi: 10.1097/00002480-199809000-00008.
The authors previously reported the development of a blood filter device containing immobilized protamine (termed "protamine filter") that could be used at the conclusion of an extracorporeal blood procedure to prevent heparin and protamine induced complications. In vitro and in vivo experiments have fully demonstrated the feasibility and utility of the approach. The bottleneck limitations of this approach, however, lie in the lack of efficacy and capacity of the filter device. In this article, the authors describe a method to improve the efficacy in heparin adsorption, by incorporating a poly(ethylene glycol) spacer arm between the immobilized protamine and the fiber surface to enhance its freedom to dynamic motion. The authors also describe a method to increase the capacity of the filter, by using a poly-L-lysine based amplification method to augment protamine loading on the fiber, and to create multiple layers of immobilized protamine for heparin adsorption. Results show that with a poly(ethylene glycol) spacer arm of 3,400 Da, heparin adsorption on the protamine-poly(ethylene glycol) fibers was increased dramatically from a value of 9.1 mg heparin per gram of fibers in the control (i.e., without the poly[ethylene glycol] spacer) to 60 mg heparin/g fiber. The use of the amplification method with 110 kDa poly-L-lysine also yielded a threefold increase in protamine loading, and, consequently, an approximately fourfold enhancement in heparin adsorption (from 9.1 to 38.0 mg heparin/g fiber). A combination of these two methods would yield an optimized protamine filter that could meet all types of clinical needs in heparin removal. As assessed from the in vivo theoretical model reported previously for the protamine filter, a 95% heparin removal under cardiopulmonary bypass conditions could be achieved with a single optimized protamine filter with a size smaller than a hemodialyzer cartridge.
作者之前报道了一种含有固定化鱼精蛋白的血液过滤装置(称为“鱼精蛋白过滤器”)的研发,该装置可在体外血液操作结束时使用,以预防肝素和鱼精蛋白引起的并发症。体外和体内实验已充分证明了该方法的可行性和实用性。然而,该方法的瓶颈限制在于过滤装置的效力和容量不足。在本文中,作者描述了一种提高肝素吸附效力的方法,即在固定化鱼精蛋白和纤维表面之间引入聚乙二醇间隔臂,以增强其动态运动的自由度。作者还描述了一种增加过滤器容量的方法,即使用基于聚-L-赖氨酸的扩增方法来增加纤维上鱼精蛋白的负载量,并创建多层固定化鱼精蛋白用于肝素吸附。结果表明,使用3400 Da的聚乙二醇间隔臂时,鱼精蛋白-聚乙二醇纤维上的肝素吸附量从对照(即没有聚乙二醇间隔臂)时的每克纤维9.1毫克肝素显著增加到60毫克肝素/克纤维。使用110 kDa聚-L-赖氨酸的扩增方法也使鱼精蛋白负载量增加了三倍,因此肝素吸附量提高了约四倍(从9.1毫克肝素/克纤维增加到38.0毫克肝素/克纤维)。这两种方法的结合将产生一种优化的鱼精蛋白过滤器,能够满足肝素去除方面的所有类型临床需求。根据之前报道的鱼精蛋白过滤器的体内理论模型评估,使用一个尺寸小于血液透析器滤芯的单一优化鱼精蛋白过滤器,在体外循环条件下可实现95%的肝素去除率。